Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that its Cupric Chloride has received approval from the National Medical Products Administration of China for market preparations. This approval marks the third of its kind for PRC entities, indicating a significant step in the company’s product development and potential market expansion, enhancing its position in the pharmaceutical industry.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of bulk drugs. The company is involved in creating products such as Cupric Chloride, which is used in medical applications like Multi-Trace Elements Injection for supplementing trace elements.
YTD Price Performance: -16.93%
Average Trading Volume: 12,678,254
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.47B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.